BioSpace News Archive

Artificial intelligence and advanced visualization technology innovator TeraRecon has been awarded two first-of-its-kind technology patents from the U.S. Patent and Trademark Office.

DENTSPLY SIRONA Inc., The Dental Solutions Company, announced its financial results for the three and twelve months ended December 31, 2019.

Advocare, a physician-owned multi-specialty group with nearly 600 providers, continues to expand its footprint in New Jersey and Pennsylvania by welcoming five new independent physician practices into the organization.

Zhongchao Inc. announced that Network 1 Financial Securities, Inc., who acted as the lead underwriter and bookrunner of the Company’s initial public offering, has partially exercised their over-allotment option and purchased an additional 315,003 Class A ordinary shares at the IPO price of $4.00 per share.

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced it will host a conference call and webcast on Monday, March 9, 2020 at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2019 operating and financial results.

Neon Therapeutics, Inc. (Nasdaq: NTGN) today reported financial results for the fourth quarter and full-year ended December 31, 2019 and provided a business update.

Recro, Inc. (NASDAQ:REPH) a leading contract development and manufacturing organization (CDMO) with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that it will report year end 2019 financial results on Wednesday, March 4, 2020.

EyePoint Pharmaceuticals, Inc. announced positive topline 36-month follow-up data from the second Phase 3 trial of YUTIQ® 0.18 mg three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

China Pharmaceutical Holdings Limited (NYSE American: CPHI) (“China Pharma” or “Company”), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced that its subsidiary, Hainan Helpson Pharmaceutical & Biotechnology Co., Ltd. (“Helpson”) launched a new product.